By Elias Schisgall

Corcept Therapeutics swung to a loss in the first quarter and said a Phase 2 study of an ALS treatment failed to meet its primary endpoint.

The pharmaceutical company said Thursday that the trial of dazucorilant didn't meet a primary endpoint of a difference in function between patients who received the treatment and a placebo group.

Despite missing the endpoint, the company said patients who received a higher dose of the drug for a two-year period had an 87% reduction in the risk of death. Overall survival was a secondary endpoint for the study, Corcept said.

"Our data demonstrate that dazucorilant markedly reduces mortality in the first years following diagnosis, when people with ALS retain meaningful function and quality of life," Corcept Chief Development Officer Bill Guyer said. "We are working with regulators to advance this program as expeditiously as possible and expect to initiate a pivotal Phase 3 study later this year."

The company also reported a first-quarter loss of $31.8 million, or 30 cents a share, compared with a profit of $20.3 million, or 17 cents a share, a year earlier.

Revenue rose to $164.9 million, up from $157.2 million, a year prior.

Analysts polled by FactSet were expecting a loss of 11 cents a share on revenue of $185.8 million.

The company lifted its full-year revenue outlook, projecting revenue between $950 million and $1.05 billion. Analysts are expecting $899.5 million.

Shares of Corcept were up 1% to $47.00 in after-hours trading after dipping into the red after the bell. The stock closed flat at $46.52, up 34% this year.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

Corcept reported that its ALS treatment, dazucorilant, didn't meet its primary endpoint in a Phase 2 study in December 2024. "Corcept Therapeutics Swings to Loss, Says ALS Drug Didn't Meet Primary Endpoint" at 6:47 p.m. ET incorrectly suggested that Corcept reported the study failing to meet its primary endpoint on Thursday. The correct version follows:

By Elias Schisgall

Corcept Therapeutics swung to a loss in the first quarter and said a Phase 2 study of an ALS treatment showed improved survival rates.

The pharmaceutical company said Thursday that patients who received a higher dose of dazucorilant for a two-year period had an 87% reduction in the risk of death. Overall survival was a secondary endpoint for the study, Corcept said.

Corcept reported in December 2024 that dazucorilant didn't meet a primary endpoint of a difference in function between patients who received the treatment and a placebo group.

"Our data demonstrate that dazucorilant markedly reduces mortality in the first years following diagnosis, when people with ALS retain meaningful function and quality of life," Corcept Chief Development Officer Bill Guyer said. "We are working with regulators to advance this program as expeditiously as possible and expect to initiate a pivotal Phase 3 study later this year."

The company also reported a first-quarter loss of $31.8 million, or 30 cents a share, compared with a profit of $20.3 million, or 17 cents a share, a year earlier.

Revenue rose to $164.9 million, up from $157.2 million, a year prior.

Analysts polled by FactSet were expecting a loss of 11 cents a share on revenue of $185.8 million.

The company lifted its full-year revenue outlook, projecting revenue between $950 million and $1.05 billion. Analysts are expecting $899.5 million.

Shares of Corcept were up 1% to $47.00 in after-hours trading after dipping into the red after the bell. The stock closed flat at $46.52, up 34% this year.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

May 01, 2026 08:44 ET (12:44 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.